LW was original brought in to help determine the value of the B-OM landscape when it came to licensing/partnership. After they finished their review of B Leo hires them to basically be the interface between IPIX and any potential deals made for B-OM.

With the current situation I would be surprised if they’re apart of negotiations with the government/Labs/ potential licensing/partnership discussions for COVID-19 as well. I’m assuming this based of LW current push in the COVID market based off their past market snapshots they’ve recently put out.

There is also the B-OM Ph3 that’s ready to move forward once funding is found so a partnership could be announced any day. These negotiations take time so I couldn’t even come up with a timeline.


I do feel though any non COVID clinical trial would be a snails pace right now but I would also like to mention with the free research being handled on the COVID side that they might wait on B-OM.

If B is moved at warp speed which it is being done and if approved for COVID it would command 10s of millions more on the B-OM side for a PH3 deal. I think it’s worth the wait.